Larazotide Peptide Potentiates Immune Checkpoint Inhibitor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immune checkpoint inhibitors, such as PD-1 blockade therapy, often fail to respond or result in resistance in cancer patients, necessitating a method to enhance their efficacy.
Innovation Solution
Administering larazotide or its derivatives to promote tight junction integrity in the intestinal epithelium, potentially potentiating the effectiveness of immune checkpoint inhibitor therapies by reducing paracellular permeability and improving the integrity of both intestinal and endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitor therapy is administered to cancer patients, then cancer treatment efficacy is improved, but treatment response is insufficient or resistance develops in many patients
Solution Approach 1:
Larazotide acts as an intermediary substance that modifies the physiological environment (intestinal barrier function) to enhance the effectiveness of immune checkpoint inhibitors. The peptide promotes tight junction integrity and reduces paracellular permeability in the gut, creating conditions that potentiate the cancer therapy's efficacy without directly interacting with the tumor or immune checkpoint pathways
Solution Approach 2:
The invention changes physiological parameters of the intestinal barrier (tight junction integrity, paracellular permeability) through larazotide administration. These parameter changes in the gut environment subsequently influence the systemic immune response and enhance checkpoint inhibitor therapy effectiveness, representing a indirect parameter modification approach to improve cancer treatment
2Reliability
If larazotide is administered to promote tight junction integrity, then intestinal barrier function is improved, but the mechanism for enhancing cancer therapy efficacy is not fully understood
Solution Approach 1:
Larazotide serves a dual function: it directly promotes tight junction integrity and reduces paracellular permeability in the intestinal epithelium, while simultaneously these same actions create the therapeutic potentiation effect. The substance's primary physiological function (barrier maintenance) is itself the mechanism for enhancing cancer therapy, eliminating the need for separate explanatory mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Larazotide or its derivatives enhance the efficacy of immune checkpoint inhibitor therapies, particularly in patients who have not responded or have developed resistance, by maintaining a healthy gut mucosa and improving the response to treatments like anti-PD-1 or anti-CTLA-4 therapies, as demonstrated by slowed tumor progression and prolonged survival in animal models.
Implementation Method 1
Larazotide is a peptide that promotes tight junction integrity and reduces paracellullar permeability, including permeability of the intestinal epithelium
Implementation Method 2
larazotide administration, or administration of a larazotide derivative (e.g., having one or more (d)-amino acids, potentiates immune checkpoint inhibitor therapy
Data Source
AI summary
The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.